Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis

Breast Cancer Research and Treatment

Volumn 164, Issue 3, 2017, Pages 581-591

  Lewis Phillips, Gail D ^a   Nishimura, Merry C ^a   Lacap, Jennifer Arca ^a   Kharbanda, Samir ^b   Mai, Elaine ^a   Tien, Janet ^a   Malesky, Kimberly ^c   Williams, Simon P ^a   Marik, Jan ^a   Phillips, Heidi S ^a  

^a GENENTECH INC   (United States)

^b Calico Life Sciences LLC   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Blood brain barrier; Brain metastasis; Breast cancer; T DM1; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; GNE 317; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MUMAB 4D5; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; ZIRCONIUM 89; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; GNE-317; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PYRIMIDINE DERIVATIVE; THIOPHENE DERIVATIVE; ZIRCONIUM-89-TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN DAMAGE; BRAIN GRAFT; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; BREAST CANCER CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; LOADING DRUG DOSE; MAMMARY GLAND FAT; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT DURATION; ANIMAL; BREAST TUMOR; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; SECONDARY; SURVIVAL ANALYSIS; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MICE; MICE, TRANSGENIC; PYRIMIDINES; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; THIOPHENES; TISSUE DISTRIBUTION; TRASTUZUMAB; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85019079104     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-017-4279-4     Document Type: Article

References (34)

1. Patel RR, Mehta MP (2007) Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res 13:1675–1683
2. Wong J, Hird A, Kirou-Mauro A, Napolskikh J, Chow E (2008) Quality of life in brain metastases radiation trials: a literature review. Curr Oncol 15:25–45
3. Steeg PS, Camphausen KA, Smith QR (2011) Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 11:352–363
4. Mehta AI, Brufsky AM, Sampson JH (2013) Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treatment Rev 39:261–269
5. Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS (2013) CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res 19:6404–6418
6. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320–368
7. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:92–98
8. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA (2011) Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17:4834–4843
9. Kodack DP, Askoxylakis V, Ferraro GB, Fukumura D, Jain RK (2015) Emerging strategies for treating brain metastases from breast cancer. Cancer Cell 27:163–175
10. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L, Halverson D, Vortmeyer AO, Steinberg SM, Aldape K, Steeg PS (2007) HER2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67:4190–4198
11. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, Abdulkarim B (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24:5658–5663
12. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau S-W, Islam R, Aldape KD, Yu T-K, Hortobagyi GN, Gonzales-Angulo AM (2008) Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19:1242–1248
13. Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roche H, Liu MC, Greil R, Ciruelos E, Loibl S et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452–1459
14. Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, Jiminez M, Le Rhun E, Pierga J-Y, Goncalves A, Leheurteur M, Domont J, Gutierrez M, Cure H, Ferrero J-M, Labbe-Devilliers C (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14:64–71
15. Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, Dieckmann K, Pinker K, Bago-Horvath Z, Galid A, Oehler L, Zielinski CC, Gnant M, Steger GG, Preusser M (2015) Activity of T-DM1 in HER2-positive breast cancer brain metastases. Clin Exp Metastasis 32(7):729–737
16. Jacot W, Pons E, Frenel JS, Guiu S, Levy C, Heudel PE, Bachelot T, D’Hondt V, Darlix A, Firmin N, Romieu G, Thezenas S, Dalenc F (2016) Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Res Treat 157(2):307–318
17. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS, Smith QR (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16:5664–5678
18. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clinical Pharmacol Ther 87:586–592
19. 89Zr-labeled monoclonal antibodies for ImmunoPET. Nuclear Med Biol 37:289–297
20. Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, Mai E, Wong WL, Hollingshead P, Schwall R, Koeppen H, Erickson S (2004) HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 10:2499–2511
21. Dijkhuizen RM, Nicolay K (2003) Magnetic resonance imaging in experimental models of brain disorders. J Cereb Blood Flow Metab 23:1383–1401
22. Salphati L, Heffron TP, Alicke B, Nishimura M, Barck K, Carano RA, Cheong J, Edgar KA, Greve J, Kharbanda S, Koeppen H et al (2012) Targeting the PI3K pathway in the brain—efficacy of a PI3K inhibitors optimized to cross the blood-brain barrier. Clin Cancer Res 18:6239–6248
23. HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255–263
24. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429–440
25. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RVJ, Lutz RJ, Wong WLT, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280–9290
26. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD, Steeg PS (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100:1092–1103
27. Gril B, Palmieri D, Qian Y, Smart D, Ileva L, Liewehr DJ, Steinberg SM, Steeg PS (2011) Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin Cancer Res 17:142–153
28. Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357:39–51
29. Choi BD, Kuan CT, Cai M, Archer GE, Mitchell DA, Gedeon PC, Sanchez-Perez L, Pastan I, Bigner DD, Sampson JH (2013) Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci USA 110:270–275
30. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459–465
31. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A et al (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505–509
32. Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B (2008) HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS ONE 3:e2881
33. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh D-Y, Dieras V, Guardino E, Fang L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. New Engl J Med 367:1783–1791
34. Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, Miles D, Samant M, Welslau M, Dieras V (2015) Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis of EMILIA. Annals Oncol 26:113–119